Abstract
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Infectious Disorders - Drug Targets
Title: New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Volume: 9 Issue: 3
Author(s): S. M. Tomlinson, R. D. Malmstrom and S. J. Watowich
Affiliation:
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Abstract: Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Export Options
About this article
Cite this article as:
Tomlinson M. S., Malmstrom D. R. and Watowich J. S., New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030327
DOI https://dx.doi.org/10.2174/1871526510909030327 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy
Current Pharmaceutical Design Navigating Research Toward the Re-emerging Nipah Virus- A New Piece to the Puzzle
Current Pharmaceutical Design CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Potential Neuroprotective Effect of Cannabinoids in COVID-19 Patients
Current Topics in Medicinal Chemistry Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments
Current Medicinal Chemistry Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Reverse Vaccinology: An Epitope Based Approach to Design Vaccines
Current Bioinformatics Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design EDITORIAL
Current Signal Transduction Therapy Polymer-based Drug Delivery Systems Applied to Insects Repellents Devices: A Review
Current Drug Delivery